Aidan C A Tomlinson - 1Revolution Medicines

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 23 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers

James Cregg, Anne V Edwards, Stephanie Chang,Bianca J Lee,John E Knox,Aidan C A Tomlinson,Abby Marquez, Yang Liu, Rebecca Freilich, Naing Aay,Yingyun Wang, Lingyan Jiang, Jingjing Jiang,Zhican Wang, Michael Flagella,David Wildes, Jacqueline A M Smith,Mallika Singh,Zhengping Wang,Adrian L Gill,Elena S Koltun

Journal of medicinal chemistryno. 6 (2025): 6064-6083

Cited0Views0WOSBibtex

Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers

James Cregg, Kristof Pota,Aidan C A Tomlinson, Jason Yano,Abby Marquez, Yang Liu,Christopher J Schulze,Kyle J Seamon,Matthew Holderfield, Xing Wei, Yongxian Zhuang,Yu Chi Yang,Jingjing Jiang, Yue Huang,Ruiping Zhao, Yun Ling,Zhican Wang, Michael Flagella,Zhengping Wang,Mallika Singh,John E Knox, Robert Nichols,David Wildes,Jacqueline A M Smith,Elena S Koltun,Adrian L Gill

Journal of medicinal chemistryno. 6 (2025): 6041-6063

Cited0Views0WOSBibtex

Concurrent Inhibition of Oncogenic and Wild-Type RAS-GTP for Cancer Therapy

NATURE（2024）

Cited2Views0WOSNATUREBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn